Navamedic Asa · OSL:NAVA
Navamedic Asa — Investor Presentation (June 2025)
13 slides from Navamedic Asa's investor presentation, Jun 24, 2025
Slide 1: Navamedic expands into addiction treatment area with the acquisition of dne pharma's business
Navamedic expands into addiction treatment area with the acquisition of dne pharma’s business Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO June 24, 2025
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR measures in this presentation. These non-GAAP / non-IFRS financial measures are provided as additional insight into the INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING I
Slide 3: Key highlights
Key highlights • Navamedic has entered into an agreement to acquire the business of dne pharma for a total consideration of up to NOK 225 million, whereby NOK 185 million is payable at closing of the Acquisition, and the remaining NOK 40 million is payable in two tranches subject to achievement of c
Slide 4: Transaction overview
Transaction overview • The total consideration of up to NOK 225 million is payable in instalments, whereby NOK 185 million is payable at closing of the acquisition, and the remaining NOK 40 million is payable in two tranches subject to achievement of certain agreed sales volumes for the acquired pro
Slide 5: Financial impact Navamedic
Financial impact Navamedic • In 2024, the business being acquired generated net sales of NOK 62 million and is expected to be an important contributor to Navamedic’s growth strategy going forward • The acquisition is line with Navamedic’s strategy of increasing product ownership, and the product por
Slide 6: Transaction rationale
Transaction rationale Gives Navamedic a Addiction treatment is Seamless integration Strong fit with Expands strong strategic a fast-growing field into Navamedic’s Navamedic’s existing Navamedic’s portfolio position in an with significant impact commercial platform operations in terms of of fully own
Slide 7: Description of the dne pharma business
Description of the dne pharma business Company overview of the dne pharma business Financials development of the acquired business • Pharmaceutical company built on the remaining pharma business from NOKm Revenue “Den Norske Eterfabrikk” (est. 1900). Market leader in opioid substitution treatment in
Slide 8: European roll-out of addiction treatment business
European roll-out of addiction treatment business Focus on Europe with the potential to roll out Ventizolve® and Levopidon® globally Ventizolve® Naloxone intranasal spray ▪ Ventizolve® has been approved in 12 countries in Europe Metadon dne ▪ MENA Zone 4A stability study initiated Single dose liquid
Slide 9: Product portfolio and commercialisation status
Product portfolio and commercialisation status Key products Commercialisation status 2024 Revenue split Product launched Currently Ventizolve® MA in Methadone Levopidon Ventizolve® 30% Ventizolve 39% Naloxone nasal spray NOK 62m FI SE DK NO UK FR BE IE NL DE IT EE 2024 Revenue Currently Levopidon®1)
Slide 10: Ventizolve® – Intranasal naloxone spray for reversal of opioid overdose
Ventizolve® – Intranasal naloxone spray for reversal of opioid overdose • A needle-free solution designed to provide first responders in suspected overdose Ventizolve® with an easy-to-use, potentially life-saving dose of naloxone Naloxone intranasal spray • Product comprises a moderate dosage of 1.2
Slide 11: Nasal delivery of naloxone has many crucial benefits
Nasal delivery of naloxone has many crucial benefits Accessible and • Optimal for bystander administration • Intended to be used immediately in the event of an fast Bystanders overdose • Take-home naloxone program makes it more Family and friends Pharmacies accessible to family, friends and other fi
Slide 12: Concluding remarks
Concluding remarks • The acquisition of the dne pharma’s business adds to the range of products Navamedic now fully owns, which is part of the long-term strategy and is expected to be an important contributor to our growth going forward • The products of the acquired business fit well into the exist
Slide 13: Q&A
Q&A @ Navamedic